Quantcast

Diplomat to sell Sanofi’s and Regeneron’s rheumatoid arthritis drug in U.S.

Diplomat Pharmacy will sell Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab), recently approved by the FDA to treat adults with moderately to severely active rheumatoid arthritis (RA) who have an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs).

Read more

CHMP gives positive opinion for Sanofi’s and Regeneron’s rheumatoid arthritis drug

European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Sanofi and Regeneron Pharmaceuticals joint developed product Kevzara (sarilumab), recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis.

Read more

Eli Lilly and Company and Incyte Corporation: Positive Topline Results of RA-BEAM

Eli Lilly and Company and Incyte Corporation announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.

Read more